Billions in seven days: health innovation's biggest funding week of the year
The final week of September 2026 delivered one of the most concentrated bursts of health-technology funding on record. Across a handful of announcements, investors committed well over $1.5 billion to companies working at the intersection of artificial intelligence and healthcare — from a brand-new AI lab launching with a half-billion-dollar commitment, to a brain-computer interface company raising the largest round in its category's history outside Neuralink, to a drug-discovery startup pulling in more than $300 million. Taken together, the week's deals describe an investor class that has stopped debating whether AI will transform healthcare and started competing to own the companies doing it.
The scale is worth pausing on. Health innovation has always attracted capital, but the rounds announced in the week of September 29 share a distinctive feature: they are large, they are led by top-tier firms, and they are going to companies whose products are already inside clinical workflows or clinical trials — not to speculative research projects. This is deployment capital, not discovery capital. Investors are funding scale-up, not science experiments.
Ortet: a $500 million launch
The week's most striking announcement was also its newest company. Ortet, a New York-based frontier AI lab building what it describes as a patient-centered foundation model for health, launched with a $500 million commitment from Thoreau, the health infrastructure platform that founded the company. Half a billion dollars for a company at launch is extraordinary by any standard — it is the kind of commitment usually reserved for established businesses, not day-one labs. The structure of the deal is itself a signal: rather than raising a traditional venture round from multiple firms, Ortet was incubated and capitalized by a single health infrastructure platform, suggesting the lab's work is expected to plug directly into real clinical operations from the start.
The concept of a "patient-centered foundation model" points to where health AI is heading. General-purpose AI models are trained on the open internet; a foundation model for health would be trained on clinical data, medical literature and care pathways, with the patient — rather than the billing code or the institution — as the organizing principle. If it works, such a model could underpin everything from diagnostic assistance to care coordination. The $500 million commitment suggests Thoreau believes the opportunity is large enough to justify building the model in-house rather than licensing someone else's. Whether a single company's model can achieve the breadth and safety required for clinical use remains an open question — healthcare is where AI's hallucination problem meets its highest stakes — but the capital is now in place to find out.
Precision Neuroscience: $250 million for the brain-computer interface race
On September 24, New York-based Precision Neuroscience announced it had closed an oversubscribed $250 million Series D financing round, co-led by Pershing Square, the Ackman Oxman Institute and an undisclosed leading life-sciences investment fund. Additional participants included the Duquesne Family Office, B Capital, ARK Invest, Mubadala Capital, Hitachi Ventures and others. The round brings the company's total capital raised since its 2021 founding to $430 million, and it is the largest disclosed single round to date for a US brain-computer interface company outside Neuralink.
Precision's technology, the Layer 7 Cortical Interface, is a thin-film electrode array designed to rest on the surface of the brain rather than penetrating tissue — an approach the company positions as safer and more scalable than implantable systems that pierce brain tissue. The device received FDA clearance in April 2025 and has since been used in more than 100 patient procedures across 18 medical institutions. The company also holds a commercial partnership with Medtronic and operates its own micro-electromechanical systems manufacturing facility in Texas — an unusual degree of vertical integration for a startup, and a meaningful one in a field where manufacturing precision is part of the product.
The investor roster is as notable as the amount. Pershing Square is Bill Ackman's investment firm — not a traditional life-sciences investor — and the Ackman Oxman Institute is a philanthropic neurotechnology institute. Their co-leadership of the round, alongside sovereign-wealth-linked capital from Mubadala and a deep bench of venture firms, reflects a broadening of the investor base for brain-computer interfaces beyond specialist biotech funds. The category is being treated less like a medical device niche and more like a platform technology — one whose applications could extend from restoring movement and communication for people with paralysis to, eventually, far broader human-computer interaction.
"The next phase of BCI will be defined by more than technology alone," said Michael Mager, Precision's co-founder and CEO. "We have built the clinical network, regulatory position, and manufacturing base that leadership in this field requires. We are also putting safety at the center of our product design, forming deep partnerships with the world's leading neurosurgeons and academic medical centers, and building a company and a culture that we hope will endure. We're proud to have investors who share that long-term vision."
Mager's emphasis on clinical network, regulatory position and manufacturing — rather than on the technology itself — is the statement of a company that believes the brain-computer interface race will be won on execution, not just engineering. With more than 100 procedures completed and FDA clearance in hand, Precision is arguing that it has already crossed the chasm from promising prototype to clinical reality. The $250 million is meant to carry it from clinical reality to commercial scale.
OpenEvidence and Enveda: AI moves deeper into the clinic and the lab
Two more mega-rounds filled out the week's health AI picture. OpenEvidence, a Miami-based AI clinical search and decision-support platform for physicians, raised another $250 million led by Andreessen Horowitz and Byers Capital, with participation from hospital systems. The participation of hospital systems as investors — not just customers — is the detail that matters most. When the institutions that will deploy a clinical AI tool also put capital behind it, the usual enterprise sales friction diminishes: the buyers have literally bought in. OpenEvidence's product sits at the point of care, helping physicians search clinical evidence and make decisions — a workflow where accuracy is non-negotiable and where the trust signal of hospital-system backing carries real weight with skeptical clinicians.
Enveda Biosciences, based in Boulder, Colorado, raised $311 million in a Series E led by Catalio Capital Management, with participation from Durable Capital Partners, ICONIQ, Lightspeed, T. Rowe Price-advised accounts, Baillie Gifford and Premji Invest. The company uses AI to discover medicines from natural chemistry — essentially, training models on the vast chemical space of natural products to identify drug candidates that traditional screening would miss. The investor list, heavy with crossover funds that typically invest closer to the public markets, suggests Enveda is being valued less like an early-stage biotech and more like a late-stage platform company approaching significant inflection points. A $311 million Series E is a round sized for scale, not for exploration.
Rounding out the week's health financing activity, EliseAI — the New York company automating administrative workflows for healthcare practices and housing providers — raised $350 million at a $4 billion valuation, co-led by Andreessen Horowitz and Bessemer Venture Partners. And Rightway, a New York-based pharmacy benefits and care navigation company, raised $155 million in a Series E led by Francisco Partners, with participation from Thrive Capital and Khosla Ventures. The pharmacy benefits space is one of American healthcare's most criticized intermediaries; a $155 million bet on a technology-driven alternative suggests investors believe the model is finally vulnerable to disruption.
Why health innovation is pulling mega-rounds
Several forces are converging to make health AI the most richly funded applied-AI category of 2026. First, the demand side is structural: aging populations across the US, Europe, Australia and East Asia are increasing clinical workloads faster than the clinician supply can grow, creating genuine demand for tools that extend what each physician, nurse and administrator can do. Second, the regulatory pathway has become clearer — FDA clearances for AI-enabled devices, like the one Precision's Layer 7 received in April 2025, give investors a legible milestone to underwrite. Third, the buyers are now sophisticated: hospital systems investing directly in OpenEvidence, or a health infrastructure platform capitalizing Ortet with $500 million, indicate that healthcare incumbents have moved from AI curiosity to AI strategy.
There is also a defensive logic at work. Healthcare is one of the few sectors where AI's advantages — pattern recognition across vast datasets, 24/7 availability, consistency — map directly onto the sector's scarcest resources: specialist expertise and clinician time. Investors who missed the first wave of health AI are now paying premiums to get into the second, and founders with clinical traction can command terms that would have been unthinkable three years ago. The risk, as always with concentrated capital deployment, is that valuations begin to assume flawless execution in a sector famous for slow adoption cycles, complex reimbursement and regulatory reversals. A brain-computer interface company can have the best technology in the world and still spend years navigating FDA review for each new indication.
What the week means
For patients, the honest version of this story is that most of these technologies are years from changing anyone's care — with the partial exception of clinical decision-support tools like OpenEvidence's, which deploy inside existing workflows. Brain-computer interfaces are advancing toward commercial reality, but their near-term impact will be concentrated among people with severe paralysis and neurological injury, not the general population. AI-discovered drugs from companies like Enveda face the same decade-long clinical trial gauntlet as any other medicine. The funding is a leading indicator, not a result.
For the startup ecosystem, though, the week of September 29, 2026 will be remembered as the moment health AI graduated from a promising vertical to the center of the venture market. When a single week produces a $500 million company launch, a $350 million vertical-AI round, a $311 million drug-discovery raise and the largest non-Neuralink brain-computer interface financing ever announced, the message to founders is clear: the capital is there for health innovation with real clinical grounding. The message to everyone else is equally clear: the bar for what counts as "real" has never been higher. Investors in September 2026 are not funding health AI ideas. They are funding health AI companies with procedures completed, clearances granted, hospital systems invested and revenue growing. Everything else is, for now, waiting its turn.
Sources
